Similar articles

• Family Planning Counseling for Women With Rheumatic Diseases.

  Birru Talabi M, Clowse MEB, Schwarz EB, Callegari LS, Moreland L, Borrero S. Birru Talabi M, et al. Arthritis Care Res (Hoboken). 2018 Feb;70(2):169-174. doi: 10.1002/acr.23267. Arthritis Care Res (Hoboken). 2018. PMID: 28437837 Review. No abstract available.
• Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?

  Blalock SJ. Blalock SJ. Curr Rheumatol Rep. 2017 Feb;19(2):7. doi: 10.1007/s11926-017-0631-2. Curr Rheumatol Rep. 2017. PMID: 28164248 Review.
• Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist.

  Pincus T, Braun J, Kavanaugh A, Smolen JS. Pincus T, et al. Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S1-3. Epub 2013 Oct 3. Clin Exp Rheumatol. 2013. PMID: 24129127 No abstract available.
• Communicating the risk of side effects to rheumatic patients.

  Martin RW. Martin RW. Rheum Dis Clin North Am. 2012 Nov;38(4):653-62. doi: 10.1016/j.rdc.2012.08.007. Rheum Dis Clin North Am. 2012. PMID: 23137575 Review.
• Pharmacogenetics in the rheumatic diseases.

  Cronstein BN. Cronstein BN. Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii25-ii27. doi: 10.1136/ard.2004.028217. Ann Rheum Dis. 2004. PMID: 15479867 Free PMC article. Review. No abstract available.